EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Annexon's Enterprise Value is $-19.74 Mil.
Annexon's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $-118.01 Mil. Therefore, Annexon's EV-to-FCF for today is 0.17.
The historical rank and industry rank for Annexon's EV-to-FCF or its related term are showing as below:
ANNX'
s EV-to-FCF Range Over the Past 10 Years
Min: -7.17 Med: 0 Max: 1.18
Current: 0.08
During the past 7 years, the highest EV-to-FCF of Annexon was 1.18. The lowest was -7.17. And the median was 0.00.
ANNX's EV-to-FCF is ranked better than 94.34% of 424
companies
in the Biotechnology industry
Industry Median: 3.285
vs ANNX: 0.08
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Annexon's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Annexon's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annexon's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annexon's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Annexon's EV-to-FCF falls into.
Annexon's current Enterprise Value is $-19.74 Mil.
Annexon's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-118.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annexon (NAS:ANNX) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Annexon's share price for today is $2.40.
Annexon's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Annexon EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Annexon's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANNX has been successfully added to your 